Muutke küpsiste eelistusi

Chronic Obstructive Pulmonary Disease: A Systemic Inflammatory Disease 2017 ed. [Kõva köide]

Edited by , Edited by
Teised raamatud teemal:
  • Kõva köide
  • Hind: 141,22 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 188,29 €
  • Säästad 25%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 3-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
Chronic Obstructive Pulmonary Disease: A Systemic Inflammatory Disease 2017 ed.Suurem pilt
Teised raamatud teemal:
Teised raamatud sellest sooduspakkumisest: Kevadine sooduspakkumine - kuni 31. maini üle miljoni raamatu kuni 25% soodsamalt
Püsilink: https://www.kriso.ee/db/9789811008382.html
Märksõnad:
This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.

Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD. 

Arvustused

This is a well-written book that provides an elaborate overview of the current state of understanding about COPD and its genetics, pathogenesis, diagnosis, and treatment as well as comorbid disease conditions. As such, this book should be an essential addition for practicing pulmonologists and researchers working in the field of COPD. (Santosh Dhungana, Doodys Book Reviews, June, 2017)

Part I Definition and Epidemiology
1 Definition of Chronic Obstructive Pulmonary Disease (COPD): Is the Latest GOLD Classification of Severity Still Valid?
3(14)
Kazuhisa Asai
Kazuto Hirata
2 Epidemiology of COPD: Why Is the Disease So Poorly Recognized?
17(14)
Yoko Shibata
Part II Genetic Predisposition and Pathogenic Mechanisms
3 Genetic Predisposition to COPD: Are There Any Relevant Genes Determining the Susceptibility to Smoking?
31(26)
Takeo Ishii
Koichi Hagiwara
4 Pathogenesis of COPD (Persistence of Airway Inflammation): Why Does Airway Inflammation Persist After Cessation of Smoking?
57(16)
Akane Kato
Masayuki Hanaoka
5 Pathogenesis of COPD 3: Oxidative Stress -- Is There a Possibility of Developing New Drugs from the Standpoint of This Pathogenetic Mechanism?
73(22)
Tadashi Sato
Kuniaki Seyama
6 Pathogenesis of COPD 4 -- Cell Death, Senescence, and Autophagy: Is There a Possibility of Developing New Drugs from the Standpoint of This Pathogenetic Mechanism?
95(20)
Kazuyoshi Kuwano
Jun Araya
Hiromichi Hara
Shunsuke Minagawa
Naoki Takasaka
Saburo Ito
Katsutoshi Nakayama
Part III Comorbidities
7 Pathogenesis of Comorbidities in COPD: By What Mechanism Does Long-Term Smoking Cause Systemic Inflammation?
115(20)
Yuko Morishima
Nobuyuki Hizawa
8 Assessment of Inflammation in COPD: Are There any Biomarkers that Can be Used to Assess Pulmonary and Systemic Inflammation?
135(26)
Nobuyuki Horita
Takeshi Kaneko
Part IV Management and Treatment
9 Exercise Therapy for COPD: How Is Exercise Therapy Significant?
161(18)
Takashi Motegi
10 Nutritional Therapy for COPD: What Is the Present State of Nutritional Therapy and Is There a Possibility of Developing New Drugs?
179(16)
Takao Tsuji
11 Long-Term Oxygen Therapy (or Home Oxygen Therapy) for COPD: The Present State and Future Problems
195(16)
Keisaku Fujimoto
12 Bronchodilators for COPD: At What Stage Should Therapeutic Intervention Be Initiated?
211(34)
Takashige Kuraki
13 Inhaled Corticosteroids for COPD: Are Inhaled Corticosteroids Required in the Management of COPD?
245(22)
Masayuki Itoh
14 New Anti-inflammatory Drugs for COPD: Is There a Possibility of Developing Drugs That Can Fundamentally Suppress Inflammation?
267(12)
Yasuhiro Yamauchi
Takahide Nagase
15 Exacerbation of COPD: Why Do Exacerbations of COPD Attract Attention? Are There Any Preventive Methods?
279(20)
Masamichi Mineshita
Part V Associations with Other Respiratory Diseases
16 The Asthma-COPD Overlap Syndrome (ACOS): What Is the Significance COPD Associated with Asthma?
299(14)
Hidehiro Watanabe
17 Combined Pulmonary Fibrosis and Emphysema (CPFE): Which Symptom, Fibrosis or Emphysema, Should Be Treated Preferentially? Or Should Both Be Treated Simultaneously?
313(20)
Nariaki Kokuho
Shigeo Muro
Arata Azuma
18 Association of COPD and Lung Cancer: How Does COPD Management Change the Outcome of Treatment of Lung Cancer?
333
Shinsaku Togo
Yukiko Namba
Kazuhisa Takahashi
Editors

Hiroyuki Nakamura Department of Respiratory Medicine Tokyo Medical University Ibaraki Medical Center Ibaraki, Japan

Kazutetsu Aoshiba Department of Respiratory Medicine Tokyo Medical University Ibaraki Medical Center Ibaraki, Japan